Upon co‐uptake into recipient cells with apoptotic vesicles, RBM11 re‐splices MDM4 and cyclin D1 transcripts to generate isoforms with enhanced oncogenic potential, thereby augmenting the proliferative and resistant phenotype of post‐treatment tumor cells (40). Here, RBM11 is linked to neoplasm.